# Health In Tech, Inc. (HIT)

- Sector: Technology · Industry: Software Application
- SEC CIK: 0002019505 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002019505))
- Full page: https://inspectstocks.com/stocks/hit
- Data as of: price 2026-09-28; newest filing used 2026-08-13; latest fiscal period ended 2026-06-30

## Grade

**F-** on the balance-sheet rubric used for lenders, 0 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$3.9M |  |
| Earnings growing overall | failed | -$3.9M | $4M |
| Earnings growing recently | failed | -$3.9M | $1.3M |
| Earns well on its assets | failed | -13.3% |  |
| Book value per share growing | not answerable | $0.30 |  |

Business quality (the + / − mark): 1 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -12.0% |  |
| Healthy profit margin | failed | -12.0% |  |
| Good return on equity | failed | -23.1% |  |
| Debt under control | passed | 0.01 |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $32.8M |
| Net income, trailing twelve months | -$3.9M |
| Net margin | -12.0% |
| Return on equity | -23.1% |
| Debt to equity | 0.01 |
| Diluted EPS, trailing twelve months | -$0.07 |
| Share price | $0.87 |
| Market value | $52.1M |
| Price / sales | 1.6x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/hit)
- [Financial statements](https://inspectstocks.com/stocks/hit/financials)
- [Competitors](https://inspectstocks.com/stocks/hit/peers)
- [Earnings](https://inspectstocks.com/stocks/hit/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.